再鼎医药胃癌新药临床数据不及预期

新浪财经
Nov 06, 2025

来源:中国经营报中经记者 苏浩 卢志坤 北京报道11月5日,再鼎医药(09688.HK)发布公告,其合作伙伴安进公司已停止评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的1b/3期临床研究FORTITUDE-102。据了解,贝玛妥珠单抗是再鼎医药从Five Prime公司(后被安进收购)引进的一款靶向FGFR2b的单抗药物。本次被停止的FORTITUDE-102研究是一项1b/3期临床试验,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10